Angellaq personal page - To The Moon

Angellaq

Angellaq

No personal profile

4Follow

4Followers

0Topic

0Badge

2021-07-06

Happy 4th of July! ??

Is the Stock Market Open or Closed on Independence Day?

2021-05-10

Bullish all the way!

BioNTech EPS beats by €1.33, beats on revenue

2021-07-01

$Procter & Gamble(PG)$#inflationproof

2021-05-26

???????

Moderna says its Covid vaccine is 100% effective in teens, plans to seek FDA OK in early June

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3583404232736853","uuid":"3583404232736853","gmtCreate":1620311839190,"gmtModify":1620647243276,"name":"Angellaq","pinyin":"angellaq","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/819ba48990e156eed8f64aae01bf2650","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":4,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.08","exceedPercentage":"93.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.07","exceedPercentage":"93.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":154875129,"gmtCreate":1625508087161,"gmtModify":1703742804074,"author":{"id":"3583404232736853","authorId":"3583404232736853","name":"Angellaq","avatar":"https://static.tigerbbs.com/819ba48990e156eed8f64aae01bf2650","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583404232736853","authorIdStr":"3583404232736853"},"themes":[],"htmlText":"Happy 4th of July! ??","listText":"Happy 4th of July! ??","text":"Happy 4th of July! ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/154875129","repostId":"1109703914","repostType":4,"repost":{"id":"1109703914","pubTimestamp":1625464355,"share":"https://ttm.financial/m/news/1109703914?lang=&edition=fundamental","pubTime":"2021-07-05 13:52","market":"us","language":"en","title":"Is the Stock Market Open or Closed on Independence Day?","url":"https://stock-news.laohu8.com/highlight/detail?id=1109703914","media":"Thestreet","summary":"Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.So will the major markets open or close for the holiday?The New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.It's one of nine full-closing daysfor the stock market this year.For instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading i","content":"<p>Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.</p>\n<p>So will the major markets open or close for the holiday?</p>\n<p>The New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.</p>\n<p>It's&nbsp;one of nine full-closing daysfor the stock market this year.</p>\n<p>For instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading is scheduled for a bit more than a half-day, 9:30 a.m. to 1 p.m. ET.</p>\n<p>Normal stock-trading hours run 9:30 a.m. to 4 p.m. ET.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is the Stock Market Open or Closed on Independence Day?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs the Stock Market Open or Closed on Independence Day?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 13:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.\nSo will the major markets open or close for the...</p>\n\n<a href=\"https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109703914","content_text":"Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.\nSo will the major markets open or close for the holiday?\nThe New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.\nIt's one of nine full-closing daysfor the stock market this year.\nFor instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading is scheduled for a bit more than a half-day, 9:30 a.m. to 1 p.m. ET.\nNormal stock-trading hours run 9:30 a.m. to 4 p.m. ET.","news_type":1},"isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158610400,"gmtCreate":1625147415600,"gmtModify":1703737134880,"author":{"id":"3583404232736853","authorId":"3583404232736853","name":"Angellaq","avatar":"https://static.tigerbbs.com/819ba48990e156eed8f64aae01bf2650","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583404232736853","authorIdStr":"3583404232736853"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PG\">$Procter &amp; Gamble(PG)$</a>#inflationproof&nbsp;","listText":"<a href=\"https://laohu8.com/S/PG\">$Procter &amp; Gamble(PG)$</a>#inflationproof&nbsp;","text":"$Procter & Gamble(PG)$#inflationproof","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/158610400","isVote":1,"tweetType":1,"viewCount":553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":138764186,"gmtCreate":1621969434745,"gmtModify":1704365270872,"author":{"id":"3583404232736853","authorId":"3583404232736853","name":"Angellaq","avatar":"https://static.tigerbbs.com/819ba48990e156eed8f64aae01bf2650","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583404232736853","authorIdStr":"3583404232736853"},"themes":[],"htmlText":"???????","listText":"???????","text":"???????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138764186","repostId":"1163054830","repostType":4,"repost":{"id":"1163054830","pubTimestamp":1621947483,"share":"https://ttm.financial/m/news/1163054830?lang=&edition=fundamental","pubTime":"2021-05-25 20:58","market":"us","language":"en","title":"Moderna says its Covid vaccine is 100% effective in teens, plans to seek FDA OK in early June","url":"https://stock-news.laohu8.com/highlight/detail?id=1163054830","media":"cnbc","summary":"Moderna said Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17","content":"<div>\n<p>Moderna said Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17, making it the second shot behindPfizer's to demonstrate high efficacy in younger age groups.The ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/25/covid-vaccine-moderna-says-shot-is-100percent-effective-in-teens-plans-to-seek-fda-ok-in-june.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna says its Covid vaccine is 100% effective in teens, plans to seek FDA OK in early June</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna says its Covid vaccine is 100% effective in teens, plans to seek FDA OK in early June\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 20:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/25/covid-vaccine-moderna-says-shot-is-100percent-effective-in-teens-plans-to-seek-fda-ok-in-june.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna said Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17, making it the second shot behindPfizer's to demonstrate high efficacy in younger age groups.The ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/25/covid-vaccine-moderna-says-shot-is-100percent-effective-in-teens-plans-to-seek-fda-ok-in-june.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/05/25/covid-vaccine-moderna-says-shot-is-100percent-effective-in-teens-plans-to-seek-fda-ok-in-june.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1163054830","content_text":"Moderna said Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17, making it the second shot behindPfizer's to demonstrate high efficacy in younger age groups.The company said it plans to ask the Food and Drug Administration to expand the emergency use of its Covid vaccine for teens early next month. If approved, it would likely dramatically expand the number of shots available to middle and high school students ahead of the next school year. Pfizer and German partnerBioNTechwere clearedto use their vaccine for 12- to 15-year-olds earlier this month.\"We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents,\" Moderna CEO Stephane Bancel said in a press release. \"We remain committed to doing our part to help end the COVID-19 pandemic.\"The two-dose vaccine, which is given four weeks apart, is already authorized for adults.The phase 2/3 study the company is citing Tuesday included more than 3,700 adolescents. No cases of Covid were observed in participants who received two doses of the vaccine, while four cases were observed in the placebo group, according to the company.No significant safety concerns have been identified, and side effects generally are consistent with those seen in an earlier trial of adults, the company said. The most common side effects after the second dose were headache, fatigue, muscle pain and chills, Moderna said.The new data comes less than three weeks afterthe company disclosed in an earnings report that early data showed the shot was 96% effective at protecting against Covid in teens ages 12 to 17. That data was based on those who received at least one dose of the vaccine.The company said Tuesday the shot was shown in the trial to be 93% effective after one dose. Because children are less likely to get seriously ill, Moderna used the Centers for Disease Control and Prevention's definition of Covid-19 to calculate that figure. It requires only one symptom and a positive Covid test.U.S. regulators are expected to grant Moderna's request for use in teens. The approval process could take about a month, just in time for some summer activities and fall classes if Moderna submits the data by early June. Pfizer and BioNTech requested expanded use of their shot in adolescents on April 9, for example, and were authorized by the FDA on May 10.Vaccinating children is seen as crucial to ending the pandemic. The nation is unlikely to achieve herd immunity — when enough people in a given community have antibodies against a specific disease — until children can get vaccinated, health officials and experts say.Children make up around 20% of the total U.S. population, according to government data. Some 70% to 85% of the U.S. population needs to be vaccinated against Covid to achieve herd immunity, medical experts say, and some adults may refuse to get the shots. Though more experts now say herd immunity is looking increasingly unlikely as variants spread.Vaccinating kids may also hasten the return of in-person learning and greenlight after-school extracurricular activities such as sports, art and other in-person activities, health experts say.","news_type":1},"isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190453245,"gmtCreate":1620646856387,"gmtModify":1704346048358,"author":{"id":"3583404232736853","authorId":"3583404232736853","name":"Angellaq","avatar":"https://static.tigerbbs.com/819ba48990e156eed8f64aae01bf2650","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583404232736853","authorIdStr":"3583404232736853"},"themes":[],"htmlText":"Bullish all the way!&nbsp;","listText":"Bullish all the way!&nbsp;","text":"Bullish all the way!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/190453245","repostId":"1173680926","repostType":4,"repost":{"id":"1173680926","pubTimestamp":1620646501,"share":"https://ttm.financial/m/news/1173680926?lang=&edition=fundamental","pubTime":"2021-05-10 19:35","market":"us","language":"en","title":"BioNTech EPS beats by €1.33, beats on revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1173680926","media":"seekingalpha","summary":"(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunother","content":"<p>(May 10)&nbsp;BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended March&nbsp;31, 2021.</p><ul><li>BioNTech(NASDAQ:BNTX): Q1 GAAP EPS of&nbsp;€4.39beats by €1.33.</li><li>Revenue of €2.05B (+7300.7% Y/Y)beats by €270M.</li><li>More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021</li><li>Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyond</li><li>Announced planned expansion of global footprint toAsiawith establishment of first regional headquarters for south eastAsiainSingapore, including a fully-integrated and state-of-the art mRNA manufacturing facility</li><li>In oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech’s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials.</li></ul><p>BioNTech rose more than 8% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/f3a48b0a57f38d7cf3070a5a14b83d2b\" tg-width=\"789\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p><p><b>First quarter 2021 financial results (unaudited)</b></p><p><b>Revenues: </b>Total revenues were estimated to be €2,048.4&nbsp;million1for the three months ended March 31, 2021, compared to €27.7&nbsp;million for the three months ended March 31, 2020. The increase was mainly due to rapidly increasing the supply of COVID-19 vaccine worldwide. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. BioNTech’s commercial revenues include an estimated amount of €1,751.9&nbsp;million1comprising BioNTech’s share of gross profit from COVID-19 vaccine sales in Pfizer’s territories, which represents a net figure, as well as sales milestones. In addition, €63.9&nbsp;million sales to BioNTech’s collaboration partners of products manufactured by BioNTech and €199.8&nbsp;million direct COVID-19 vaccine sales to customers in BioNTech’s territory have been recognized.</p><p><b>Cost of Sales: </b>Cost of sales were estimated to be €233.1&nbsp;million1for the three months ended March 31, 2021, compared to €5.9&nbsp;million for the three months ended March 31, 2020. Estimated cost of sales of €223.2&nbsp;million1were recognized with respect to BioNTech’s COVID-19 vaccine sales and include Pfizer’s share of gross profits earned by BioNTech.</p><p><b>Research and Development Expenses: </b>Research and development expenses were €216.2&nbsp;million for the three months ended March 31, 2021, compared to €65.1&nbsp;million for the three months ended March 31, 2020. The increase was mainly due to an increase in research and development expenses for BioNTech’s BNT162 program, recorded as purchased services with respect to those expenses, which were initially incurred by Pfizer and subsequently charged to BioNTech under the collaboration agreement. The increase was further driven by an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements.</p><p><b>General and Administrative Expenses:</b> General and administrative expenses were €38.9&nbsp;million for the three months ended March 31, 2021, compared to €15.8&nbsp;million for the three months ended March 31, 2020. The increase was mainly due to higher expenses for professional services, an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements as well as higher insurance premiums.</p><p><b>Income Taxes: </b>Interim income taxes were €514.2&nbsp;million for the first quarter of 2021 and were recognized using the estimated annual effective income tax rate of approximately 31%.</p><p><b>Net Profit / (Loss): </b>Net profit was €1,128.1&nbsp;million for the three months ended March 31, 2021, compared to €53.4&nbsp;million net loss for the three months ended March 31, 2020.</p><p><b>Cash Position: </b>Cash and cash equivalents as of March 31, 2021 were €891.5&nbsp;million.</p><p><b>Shares Outstanding: </b>Shares outstanding as of March 31, 2021 were 241,521,065.</p><p><b>Update on current signed COVID-19 vaccine order book:</b></p><p>Estimated COVID-19 vaccine revenues&nbsp;to BioNTech&nbsp;upon delivery of currently signed supply contracts of ~1.8&nbsp;billion doses is ~€12.4&nbsp;billion.</p><p>This revenue estimate reflects:</p><ul><li>Expected revenues from direct COVID-19 vaccine sales to customers in BioNTech’s territory</li><li>Expected revenues from sales to collaboration partners of products manufactured by BioNTech</li><li>Expected sales milestone payments from collaboration partners</li><li>Expected revenues related to share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territories</li></ul><p>Additional revenues related to further supply contracts for deliveries in 2021 expected with first contracts in place for 2022 and beyond.</p><p>Full year 2021 manufacturing capacity now targeting 3 billion doses and more than 3 billion doses for the year 2022.</p><p><b>On Track with Previously Stated 2021 Financial Outlook:</b></p><p><img src=\"https://static.tigerbbs.com/18224adc0e1a84aacccba6f816c54aa8\" tg-width=\"617\" tg-height=\"371\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech EPS beats by €1.33, beats on revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech EPS beats by €1.33, beats on revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 19:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update ...</p>\n\n<a href=\"https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1173680926","content_text":"(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended March 31, 2021.BioNTech(NASDAQ:BNTX): Q1 GAAP EPS of €4.39beats by €1.33.Revenue of €2.05B (+7300.7% Y/Y)beats by €270M.More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyondAnnounced planned expansion of global footprint toAsiawith establishment of first regional headquarters for south eastAsiainSingapore, including a fully-integrated and state-of-the art mRNA manufacturing facilityIn oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech’s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials.BioNTech rose more than 8% in premarket trading.First quarter 2021 financial results (unaudited)Revenues: Total revenues were estimated to be €2,048.4 million1for the three months ended March 31, 2021, compared to €27.7 million for the three months ended March 31, 2020. The increase was mainly due to rapidly increasing the supply of COVID-19 vaccine worldwide. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. BioNTech’s commercial revenues include an estimated amount of €1,751.9 million1comprising BioNTech’s share of gross profit from COVID-19 vaccine sales in Pfizer’s territories, which represents a net figure, as well as sales milestones. In addition, €63.9 million sales to BioNTech’s collaboration partners of products manufactured by BioNTech and €199.8 million direct COVID-19 vaccine sales to customers in BioNTech’s territory have been recognized.Cost of Sales: Cost of sales were estimated to be €233.1 million1for the three months ended March 31, 2021, compared to €5.9 million for the three months ended March 31, 2020. Estimated cost of sales of €223.2 million1were recognized with respect to BioNTech’s COVID-19 vaccine sales and include Pfizer’s share of gross profits earned by BioNTech.Research and Development Expenses: Research and development expenses were €216.2 million for the three months ended March 31, 2021, compared to €65.1 million for the three months ended March 31, 2020. The increase was mainly due to an increase in research and development expenses for BioNTech’s BNT162 program, recorded as purchased services with respect to those expenses, which were initially incurred by Pfizer and subsequently charged to BioNTech under the collaboration agreement. The increase was further driven by an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements.General and Administrative Expenses: General and administrative expenses were €38.9 million for the three months ended March 31, 2021, compared to €15.8 million for the three months ended March 31, 2020. The increase was mainly due to higher expenses for professional services, an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements as well as higher insurance premiums.Income Taxes: Interim income taxes were €514.2 million for the first quarter of 2021 and were recognized using the estimated annual effective income tax rate of approximately 31%.Net Profit / (Loss): Net profit was €1,128.1 million for the three months ended March 31, 2021, compared to €53.4 million net loss for the three months ended March 31, 2020.Cash Position: Cash and cash equivalents as of March 31, 2021 were €891.5 million.Shares Outstanding: Shares outstanding as of March 31, 2021 were 241,521,065.Update on current signed COVID-19 vaccine order book:Estimated COVID-19 vaccine revenues to BioNTech upon delivery of currently signed supply contracts of ~1.8 billion doses is ~€12.4 billion.This revenue estimate reflects:Expected revenues from direct COVID-19 vaccine sales to customers in BioNTech’s territoryExpected revenues from sales to collaboration partners of products manufactured by BioNTechExpected sales milestone payments from collaboration partnersExpected revenues related to share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territoriesAdditional revenues related to further supply contracts for deliveries in 2021 expected with first contracts in place for 2022 and beyond.Full year 2021 manufacturing capacity now targeting 3 billion doses and more than 3 billion doses for the year 2022.On Track with Previously Stated 2021 Financial Outlook:","news_type":1},"isVote":1,"tweetType":1,"viewCount":562,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":154875129,"gmtCreate":1625508087161,"gmtModify":1703742804074,"author":{"id":"3583404232736853","authorId":"3583404232736853","name":"Angellaq","avatar":"https://static.tigerbbs.com/819ba48990e156eed8f64aae01bf2650","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583404232736853","authorIdStr":"3583404232736853"},"themes":[],"htmlText":"Happy 4th of July! ??","listText":"Happy 4th of July! ??","text":"Happy 4th of July! ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/154875129","repostId":"1109703914","repostType":4,"repost":{"id":"1109703914","pubTimestamp":1625464355,"share":"https://ttm.financial/m/news/1109703914?lang=&edition=fundamental","pubTime":"2021-07-05 13:52","market":"us","language":"en","title":"Is the Stock Market Open or Closed on Independence Day?","url":"https://stock-news.laohu8.com/highlight/detail?id=1109703914","media":"Thestreet","summary":"Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.So will the major markets open or close for the holiday?The New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.It's one of nine full-closing daysfor the stock market this year.For instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading i","content":"<p>Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.</p>\n<p>So will the major markets open or close for the holiday?</p>\n<p>The New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.</p>\n<p>It's&nbsp;one of nine full-closing daysfor the stock market this year.</p>\n<p>For instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading is scheduled for a bit more than a half-day, 9:30 a.m. to 1 p.m. ET.</p>\n<p>Normal stock-trading hours run 9:30 a.m. to 4 p.m. ET.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is the Stock Market Open or Closed on Independence Day?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs the Stock Market Open or Closed on Independence Day?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 13:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.\nSo will the major markets open or close for the...</p>\n\n<a href=\"https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109703914","content_text":"Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.\nSo will the major markets open or close for the holiday?\nThe New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.\nIt's one of nine full-closing daysfor the stock market this year.\nFor instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading is scheduled for a bit more than a half-day, 9:30 a.m. to 1 p.m. ET.\nNormal stock-trading hours run 9:30 a.m. to 4 p.m. ET.","news_type":1},"isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190453245,"gmtCreate":1620646856387,"gmtModify":1704346048358,"author":{"id":"3583404232736853","authorId":"3583404232736853","name":"Angellaq","avatar":"https://static.tigerbbs.com/819ba48990e156eed8f64aae01bf2650","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583404232736853","authorIdStr":"3583404232736853"},"themes":[],"htmlText":"Bullish all the way!&nbsp;","listText":"Bullish all the way!&nbsp;","text":"Bullish all the way!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/190453245","repostId":"1173680926","repostType":4,"repost":{"id":"1173680926","pubTimestamp":1620646501,"share":"https://ttm.financial/m/news/1173680926?lang=&edition=fundamental","pubTime":"2021-05-10 19:35","market":"us","language":"en","title":"BioNTech EPS beats by €1.33, beats on revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1173680926","media":"seekingalpha","summary":"(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunother","content":"<p>(May 10)&nbsp;BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended March&nbsp;31, 2021.</p><ul><li>BioNTech(NASDAQ:BNTX): Q1 GAAP EPS of&nbsp;€4.39beats by €1.33.</li><li>Revenue of €2.05B (+7300.7% Y/Y)beats by €270M.</li><li>More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021</li><li>Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyond</li><li>Announced planned expansion of global footprint toAsiawith establishment of first regional headquarters for south eastAsiainSingapore, including a fully-integrated and state-of-the art mRNA manufacturing facility</li><li>In oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech’s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials.</li></ul><p>BioNTech rose more than 8% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/f3a48b0a57f38d7cf3070a5a14b83d2b\" tg-width=\"789\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p><p><b>First quarter 2021 financial results (unaudited)</b></p><p><b>Revenues: </b>Total revenues were estimated to be €2,048.4&nbsp;million1for the three months ended March 31, 2021, compared to €27.7&nbsp;million for the three months ended March 31, 2020. The increase was mainly due to rapidly increasing the supply of COVID-19 vaccine worldwide. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. BioNTech’s commercial revenues include an estimated amount of €1,751.9&nbsp;million1comprising BioNTech’s share of gross profit from COVID-19 vaccine sales in Pfizer’s territories, which represents a net figure, as well as sales milestones. In addition, €63.9&nbsp;million sales to BioNTech’s collaboration partners of products manufactured by BioNTech and €199.8&nbsp;million direct COVID-19 vaccine sales to customers in BioNTech’s territory have been recognized.</p><p><b>Cost of Sales: </b>Cost of sales were estimated to be €233.1&nbsp;million1for the three months ended March 31, 2021, compared to €5.9&nbsp;million for the three months ended March 31, 2020. Estimated cost of sales of €223.2&nbsp;million1were recognized with respect to BioNTech’s COVID-19 vaccine sales and include Pfizer’s share of gross profits earned by BioNTech.</p><p><b>Research and Development Expenses: </b>Research and development expenses were €216.2&nbsp;million for the three months ended March 31, 2021, compared to €65.1&nbsp;million for the three months ended March 31, 2020. The increase was mainly due to an increase in research and development expenses for BioNTech’s BNT162 program, recorded as purchased services with respect to those expenses, which were initially incurred by Pfizer and subsequently charged to BioNTech under the collaboration agreement. The increase was further driven by an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements.</p><p><b>General and Administrative Expenses:</b> General and administrative expenses were €38.9&nbsp;million for the three months ended March 31, 2021, compared to €15.8&nbsp;million for the three months ended March 31, 2020. The increase was mainly due to higher expenses for professional services, an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements as well as higher insurance premiums.</p><p><b>Income Taxes: </b>Interim income taxes were €514.2&nbsp;million for the first quarter of 2021 and were recognized using the estimated annual effective income tax rate of approximately 31%.</p><p><b>Net Profit / (Loss): </b>Net profit was €1,128.1&nbsp;million for the three months ended March 31, 2021, compared to €53.4&nbsp;million net loss for the three months ended March 31, 2020.</p><p><b>Cash Position: </b>Cash and cash equivalents as of March 31, 2021 were €891.5&nbsp;million.</p><p><b>Shares Outstanding: </b>Shares outstanding as of March 31, 2021 were 241,521,065.</p><p><b>Update on current signed COVID-19 vaccine order book:</b></p><p>Estimated COVID-19 vaccine revenues&nbsp;to BioNTech&nbsp;upon delivery of currently signed supply contracts of ~1.8&nbsp;billion doses is ~€12.4&nbsp;billion.</p><p>This revenue estimate reflects:</p><ul><li>Expected revenues from direct COVID-19 vaccine sales to customers in BioNTech’s territory</li><li>Expected revenues from sales to collaboration partners of products manufactured by BioNTech</li><li>Expected sales milestone payments from collaboration partners</li><li>Expected revenues related to share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territories</li></ul><p>Additional revenues related to further supply contracts for deliveries in 2021 expected with first contracts in place for 2022 and beyond.</p><p>Full year 2021 manufacturing capacity now targeting 3 billion doses and more than 3 billion doses for the year 2022.</p><p><b>On Track with Previously Stated 2021 Financial Outlook:</b></p><p><img src=\"https://static.tigerbbs.com/18224adc0e1a84aacccba6f816c54aa8\" tg-width=\"617\" tg-height=\"371\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech EPS beats by €1.33, beats on revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech EPS beats by €1.33, beats on revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 19:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update ...</p>\n\n<a href=\"https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1173680926","content_text":"(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended March 31, 2021.BioNTech(NASDAQ:BNTX): Q1 GAAP EPS of €4.39beats by €1.33.Revenue of €2.05B (+7300.7% Y/Y)beats by €270M.More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyondAnnounced planned expansion of global footprint toAsiawith establishment of first regional headquarters for south eastAsiainSingapore, including a fully-integrated and state-of-the art mRNA manufacturing facilityIn oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech’s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials.BioNTech rose more than 8% in premarket trading.First quarter 2021 financial results (unaudited)Revenues: Total revenues were estimated to be €2,048.4 million1for the three months ended March 31, 2021, compared to €27.7 million for the three months ended March 31, 2020. The increase was mainly due to rapidly increasing the supply of COVID-19 vaccine worldwide. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. BioNTech’s commercial revenues include an estimated amount of €1,751.9 million1comprising BioNTech’s share of gross profit from COVID-19 vaccine sales in Pfizer’s territories, which represents a net figure, as well as sales milestones. In addition, €63.9 million sales to BioNTech’s collaboration partners of products manufactured by BioNTech and €199.8 million direct COVID-19 vaccine sales to customers in BioNTech’s territory have been recognized.Cost of Sales: Cost of sales were estimated to be €233.1 million1for the three months ended March 31, 2021, compared to €5.9 million for the three months ended March 31, 2020. Estimated cost of sales of €223.2 million1were recognized with respect to BioNTech’s COVID-19 vaccine sales and include Pfizer’s share of gross profits earned by BioNTech.Research and Development Expenses: Research and development expenses were €216.2 million for the three months ended March 31, 2021, compared to €65.1 million for the three months ended March 31, 2020. The increase was mainly due to an increase in research and development expenses for BioNTech’s BNT162 program, recorded as purchased services with respect to those expenses, which were initially incurred by Pfizer and subsequently charged to BioNTech under the collaboration agreement. The increase was further driven by an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements.General and Administrative Expenses: General and administrative expenses were €38.9 million for the three months ended March 31, 2021, compared to €15.8 million for the three months ended March 31, 2020. The increase was mainly due to higher expenses for professional services, an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements as well as higher insurance premiums.Income Taxes: Interim income taxes were €514.2 million for the first quarter of 2021 and were recognized using the estimated annual effective income tax rate of approximately 31%.Net Profit / (Loss): Net profit was €1,128.1 million for the three months ended March 31, 2021, compared to €53.4 million net loss for the three months ended March 31, 2020.Cash Position: Cash and cash equivalents as of March 31, 2021 were €891.5 million.Shares Outstanding: Shares outstanding as of March 31, 2021 were 241,521,065.Update on current signed COVID-19 vaccine order book:Estimated COVID-19 vaccine revenues to BioNTech upon delivery of currently signed supply contracts of ~1.8 billion doses is ~€12.4 billion.This revenue estimate reflects:Expected revenues from direct COVID-19 vaccine sales to customers in BioNTech’s territoryExpected revenues from sales to collaboration partners of products manufactured by BioNTechExpected sales milestone payments from collaboration partnersExpected revenues related to share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territoriesAdditional revenues related to further supply contracts for deliveries in 2021 expected with first contracts in place for 2022 and beyond.Full year 2021 manufacturing capacity now targeting 3 billion doses and more than 3 billion doses for the year 2022.On Track with Previously Stated 2021 Financial Outlook:","news_type":1},"isVote":1,"tweetType":1,"viewCount":562,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158610400,"gmtCreate":1625147415600,"gmtModify":1703737134880,"author":{"id":"3583404232736853","authorId":"3583404232736853","name":"Angellaq","avatar":"https://static.tigerbbs.com/819ba48990e156eed8f64aae01bf2650","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583404232736853","authorIdStr":"3583404232736853"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PG\">$Procter &amp; Gamble(PG)$</a>#inflationproof&nbsp;","listText":"<a href=\"https://laohu8.com/S/PG\">$Procter &amp; Gamble(PG)$</a>#inflationproof&nbsp;","text":"$Procter & Gamble(PG)$#inflationproof","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/158610400","isVote":1,"tweetType":1,"viewCount":553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":138764186,"gmtCreate":1621969434745,"gmtModify":1704365270872,"author":{"id":"3583404232736853","authorId":"3583404232736853","name":"Angellaq","avatar":"https://static.tigerbbs.com/819ba48990e156eed8f64aae01bf2650","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583404232736853","authorIdStr":"3583404232736853"},"themes":[],"htmlText":"???????","listText":"???????","text":"???????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138764186","repostId":"1163054830","repostType":4,"repost":{"id":"1163054830","pubTimestamp":1621947483,"share":"https://ttm.financial/m/news/1163054830?lang=&edition=fundamental","pubTime":"2021-05-25 20:58","market":"us","language":"en","title":"Moderna says its Covid vaccine is 100% effective in teens, plans to seek FDA OK in early June","url":"https://stock-news.laohu8.com/highlight/detail?id=1163054830","media":"cnbc","summary":"Moderna said Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17","content":"<div>\n<p>Moderna said Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17, making it the second shot behindPfizer's to demonstrate high efficacy in younger age groups.The ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/25/covid-vaccine-moderna-says-shot-is-100percent-effective-in-teens-plans-to-seek-fda-ok-in-june.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna says its Covid vaccine is 100% effective in teens, plans to seek FDA OK in early June</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna says its Covid vaccine is 100% effective in teens, plans to seek FDA OK in early June\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 20:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/25/covid-vaccine-moderna-says-shot-is-100percent-effective-in-teens-plans-to-seek-fda-ok-in-june.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna said Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17, making it the second shot behindPfizer's to demonstrate high efficacy in younger age groups.The ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/25/covid-vaccine-moderna-says-shot-is-100percent-effective-in-teens-plans-to-seek-fda-ok-in-june.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/05/25/covid-vaccine-moderna-says-shot-is-100percent-effective-in-teens-plans-to-seek-fda-ok-in-june.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1163054830","content_text":"Moderna said Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17, making it the second shot behindPfizer's to demonstrate high efficacy in younger age groups.The company said it plans to ask the Food and Drug Administration to expand the emergency use of its Covid vaccine for teens early next month. If approved, it would likely dramatically expand the number of shots available to middle and high school students ahead of the next school year. Pfizer and German partnerBioNTechwere clearedto use their vaccine for 12- to 15-year-olds earlier this month.\"We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents,\" Moderna CEO Stephane Bancel said in a press release. \"We remain committed to doing our part to help end the COVID-19 pandemic.\"The two-dose vaccine, which is given four weeks apart, is already authorized for adults.The phase 2/3 study the company is citing Tuesday included more than 3,700 adolescents. No cases of Covid were observed in participants who received two doses of the vaccine, while four cases were observed in the placebo group, according to the company.No significant safety concerns have been identified, and side effects generally are consistent with those seen in an earlier trial of adults, the company said. The most common side effects after the second dose were headache, fatigue, muscle pain and chills, Moderna said.The new data comes less than three weeks afterthe company disclosed in an earnings report that early data showed the shot was 96% effective at protecting against Covid in teens ages 12 to 17. That data was based on those who received at least one dose of the vaccine.The company said Tuesday the shot was shown in the trial to be 93% effective after one dose. Because children are less likely to get seriously ill, Moderna used the Centers for Disease Control and Prevention's definition of Covid-19 to calculate that figure. It requires only one symptom and a positive Covid test.U.S. regulators are expected to grant Moderna's request for use in teens. The approval process could take about a month, just in time for some summer activities and fall classes if Moderna submits the data by early June. Pfizer and BioNTech requested expanded use of their shot in adolescents on April 9, for example, and were authorized by the FDA on May 10.Vaccinating children is seen as crucial to ending the pandemic. The nation is unlikely to achieve herd immunity — when enough people in a given community have antibodies against a specific disease — until children can get vaccinated, health officials and experts say.Children make up around 20% of the total U.S. population, according to government data. Some 70% to 85% of the U.S. population needs to be vaccinated against Covid to achieve herd immunity, medical experts say, and some adults may refuse to get the shots. Though more experts now say herd immunity is looking increasingly unlikely as variants spread.Vaccinating kids may also hasten the return of in-person learning and greenlight after-school extracurricular activities such as sports, art and other in-person activities, health experts say.","news_type":1},"isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}